Hidetaka Niizuma

Hidetaka Niizuma

Auto-generated profile, based on publicly available information

Hidetaka Niizuma

Department of Pediatrics Tohoku University School of Medicine Sendai Japan

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2015 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
PDF file
YWYuko Watanabe
Yuko Watanabe
KSKosuke Shido
Kosuke Shido
TNTetsuya Niihori
Tetsuya Niihori
HNHidetaka Niizuma
Hidetaka Niizuma
YKYu Katata
Yu Katata
SKShigeo Kure
Shigeo Kure
Genetic mosaicism for somatic mutations of oncogenes is common in genodermatoses, which can be complicated with extra‐cutaneous abnormalities. Here we describe an infant with a congenital anaplastic astrocytoma, a linear syringocystadenoma papilliferum, and ocular abnormalities. The BRAF c.1799T>A p.V600E mutation was detected in both the brain and skin tumor cells but not in the blood or normal skin cells, suggesting somatic mosaicsism for the mutation. Clinically, the brain tumor gradually became life threatening without any response to conventional chemotherapies including carboplatin, etoposide, and temozolomide. Vemurafenib, a BRAF p.V600E inhibitor, was administered daily after the detection of the BRAF mutation. This single‐agent therapy was dramatically effective against the anaplastic astrocytoma; the tumor regressed, the cerebrospinal fluid cell count and protein levels decreased to normal levels, and hydrocephalus resolved. Moreover, other lesions including a corneal cyst also responded to vemurafenib. The brain tumor continued shrinking after 6 months of treatment. We present a genodermatosis syndrome associated with BRAF c.1799T>A p.V600E mosaicism. This syndrome may represent a new entity in the mosaic RASopathies, partly overlapping with Schimmelpenning‐Feuerstein‐Mims syndrome, which is driven by mosaicism of HRAS and/or KRAS activating mutations. Screening for BRAF c.1799T>A p.V600E is especially useful for those with malignant tumors, because it is one of the most‐druggable targets.

17 October 2022 in Cancer Medicine
Verified
Journal Article
Open access
HSHidekazu Shirota
Hidekazu Shirota
KKKeigo Komine
Keigo Komine
MTMasanobu Takahashi
Masanobu Takahashi
STShin Takahashi
Shin Takahashi
EMEisaku Miyauchi
Eisaku Miyauchi
CIChikashi Ishioka
Chikashi Ishioka
Background: A paradigm shift has occurred in cancer chemotherapy from tumor‐specific treatment with cytotoxic agents to personalized medicine with molecular‐targeted drugs. Thus, it is essential to identify genomic alterations and molecular features to recommend effective targeted molecular medicines regardless of the tumor site. Nevertheless, it takes considerable expertise to identify treatment targets from primary‐sequencing data in order to provide drug recommendations. The Molecular Tumor Board (MTB) denotes a platform that integrates clinical and molecular features for clinical decisions.Methods: This study retrospectively analyses all the cases of discussion and decision at the MTB in Tohoku University Hospital and summarizes genetic alterations and treatment recommendations.Results: The MTB discussed 1003 comprehensive genomic profiling (CGP) tests conducted in patients with solid cancer, and the resulting rate of assessing treatment recommendations was approximately 19%. Among hundreds of genes in the CGP test, only 30 genetic alterations or biomarkers were used to make treatment recommendations. The leading biomarkers that led to treatment recommendations were tumor mutational burden‐high (TMB‐H) (n = 32), ERBB2 amplification (n = 24), BRAF V600E (n = 16), and BRCA1/2 alterations (n = 32). Thyroid cancer accounted for most cancer cases for which treatment recommendation was provided (81.3%), followed by non‐small cell lung cancer (42.4%) and urologic cancer (31.3%). The number of tests performed for gastrointestinal cancers was high (n = 359); however, the treatment recommendations for the same were below average (13%).Conclusion: The results of this study may be used to simplify treatment recommendations from the CGP reports and help select patients for testing, thereby increasing the accuracy of personalized medicine.

22 April 2022 in Clinical Endocrinology
Verified
Journal Article
Closed access
AUAkari Utsunomiya
Akari Utsunomiya
SGSatoshi Goda
Satoshi Goda
SHSeiichi Hayakawa
Seiichi Hayakawa
SSSakata Sonoko
Sakata Sonoko
EHEwout J. Hoorn
Ewout J. Hoorn
THTakeshi Y. Hiyama
Takeshi Y. Hiyama

11 August 2011 in Pediatric Transplantation
Verified
Journal Article
Closed access
PDF file
HNHidetaka Niizuma
Hidetaka Niizuma
MUMitsugu Uematsu
Mitsugu Uematsu
OSOsamu Sakamoto
Osamu Sakamoto
TUToru Uchiyama
Toru Uchiyama
SHSatoshi Horino
Satoshi Horino
STShigeru Tsuchiya
Shigeru Tsuchiya

9 August 2020 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
YNYoshiko Nakano
Yoshiko Nakano
YWYuko Watanabe
Yuko Watanabe
MHMai Honda‐Kitahara
Mai Honda‐Kitahara
YYYuki Yamagishi
Yuki Yamagishi
HNHidetaka Niizuma
Hidetaka Niizuma
KIKoichi Ichimura
Koichi Ichimura

9 August 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
HNHidetaka Niizuma
Hidetaka Niizuma
ASAdam Searleman
Adam Searleman
STShugaku Takeda
Shugaku Takeda
SAScott A. Armstrong
Scott A. Armstrong
CPChristopher Y. Park
Christopher Y. Park
JHJames J. Hsieh
James J. Hsieh
Taspase1, a highly conserved threonine protease encoded by TASP1 , cleaves nuclear histone-modifying factors and basal transcription regulators to orchestrate diverse transcription programs. Hereditary loss-of-function mutation of TASP1 has recently been reported in humans as resulting in an anomaly complex syndrome, which manifests with hematological, facial, and skeletal abnormalities. Here, we demonstrate that Taspase1-mediated cleavage of TFIIA α - β , rather than of MLL1 or MLL2, in mouse embryos was required for proper fetal liver hematopoiesis and correct segmental identities of the axial skeleton. Homozygous genetic deletion of Taspase1 disrupted embryonic hematopoietic stem cell self-renewal and quiescence states and axial skeleton fates. Strikingly, mice carrying knockin noncleavable mutations of TFIIA α - β , a well-characterized basal transcription factor, displayed more pronounced fetal liver and axial skeleton defects than those with noncleavable MLL1 and MLL2, 2 trithorax group histone H3 trimethyl transferases. Our study offers molecular insights into a syndrome in humans that results from loss of TASP1 and describes an unexpected role of TFIIA α - β cleavage in embryonic cell fate decisions.